MK-677 (ibutamoren mesylate) has a terminal plasma half-life of approximately 24 hours, established in Phase 2 human pharmacokinetic studies by Chapman et al. (1996) and confirmed in subsequent clinical trials.[1][2] Its defining clinical advantage is oral bioavailability of ~60–70% — making it the only GH secretagogue that can be taken by mouth. While all other GH-releasing peptides (GHRP-2, Ipamorelin, Hexarelin, CJC-1295) require subcutaneous or intramuscular injection, MK-677 is administered as a simple once-daily oral capsule or liquid. Steady state is reached in approximately 3–5 days, with sustained elevation of both GH and IGF-1 across the dosing interval.
MK-677's terminal elimination half-life is approximately 24 hours in human subjects, based on plasma concentration data from the landmark Chapman et al. Phase 2 study published in the Journal of Clinical Endocrinology & Metabolism.[1] This figure reflects steady-state pharmacokinetics — when drug input and elimination are in equilibrium after several days of daily dosing.
Chapman et al. (1996) conducted a double-blind, placebo-controlled, crossover Phase 2 trial in elderly subjects, measuring plasma MK-677 concentrations following oral administration. Terminal elimination half-life was calculated from the log-linear decline phase of the plasma concentration–time curve after the final dose at steady state. Smith RG et al. (1997) in Science provided the foundational receptor pharmacology and confirmed the non-peptide GHS-R1a agonist mechanism that explains MK-677's oral stability.[2]
Some early studies reported shorter apparent half-lives (4–6 hours) in single-dose settings or specific assay conditions. The ~24-hour figure is considered the clinically relevant terminal elimination half-life and is the basis for once-daily dosing in all subsequent Phase 2 and Phase 3 trials.[3][4]
A critical distinction with MK-677: the plasma half-life (~24 hours) and the biological effect duration operate on different timescales. Plasma MK-677 tracks the 24-hour elimination curve. However, IGF-1 — the primary downstream anabolic biomarker reflecting sustained GH axis activation — does not mirror plasma drug levels. IGF-1 accumulates gradually over weeks of continuous MK-677 use as liver GH receptor stimulation integrates over time. After stopping MK-677, IGF-1 levels may remain elevated for approximately 1–2 weeks before returning to baseline, well beyond plasma clearance. This distinction is important for anyone interpreting bloodwork after discontinuing MK-677.
Using the standard 5 half-lives rule, MK-677 reaches approximately 97% plasma clearance after ~5 days (5 × 24 hours). The table below shows single-dose elimination; note that after reaching steady state (3–5 days of daily dosing), trough concentrations are approximately 1.5–2× higher than after a single dose due to accumulation.
| Time After Last Dose | Approx. % Remaining | Clinical Note |
|---|---|---|
| 24 hours (1 half-life) | ~50% | Active drug still present; GH elevation maintained |
| 48 hours (2 half-lives) | ~25% | Measurable reduction in GH pulsatility |
| 72 hours (3 half-lives) | ~12.5% | IGF-1 levels may begin declining |
| 96 hours (4 half-lives) | ~6% | Plasma levels approaching detection threshold |
| 120 hours / 5 days (5 half-lives) | <3% | Plasma clearance essentially complete |
MK-677's ~24-hour half-life is the pharmacological reason once-daily oral dosing is both practical and effective — a distinction that sets it apart from every other compound in the GH secretagogue class. Injectable GH-releasing peptides (GHRP-2, Ipamorelin, Hexarelin) have half-lives of 30 minutes to 2 hours, requiring multiple daily subcutaneous injections to maintain GH axis stimulation throughout the day. MK-677's long half-life produces sustained — though comparatively blunted — GH and IGF-1 elevation from a single daily oral dose.
Clinical trials have used dosing at either morning (with or without food) or bedtime. Bedtime dosing has the theoretical benefit of coinciding with the natural nocturnal GH surge, potentially amplifying the pulsatile GH release that normally peaks during slow-wave sleep. Tmax of 1–3 hours means peak plasma levels occur approximately 1–3 hours after oral administration regardless of timing.
Because MK-677 accumulates to steady state over 3–5 days, a single missed dose does not produce an abrupt drop to zero. At steady state, missing one dose will reduce trough levels by approximately 50% relative to the expected steady-state trough, but measurable plasma levels and some degree of GH/IGF-1 elevation will persist for 24–48 hours. Resuming the following day is appropriate — doubling up on a missed dose is not recommended due to dose-dependent increases in appetite, water retention, and insulin blunting.
| Compound | Half-Life | Route | GH Pattern | Cortisol Effect | Status |
|---|---|---|---|---|---|
| MK-677 (Ibutamoren) | ~24 hours | Oral | Sustained / blunted | Minimal at std. dose | Phase 2/3 completed; not approved |
| GHRP-2 | ~30 min | SC injection | Sharp pulse | Moderate increase | Research use only |
| Hexarelin | ~30–60 min | SC injection | Sharp pulse (potent) | Significant increase | Research use only |
| Ipamorelin | ~2 hours | SC injection | Selective GH pulse | Negligible | Research use only |
MK-677 was specifically developed to be orally bioavailable — this was the explicit design objective that differentiated it from peptide GH secretagogues.[2] The spiropiperidine scaffold of MK-677 confers resistance to gastrointestinal proteases that rapidly degrade peptide-based ghrelin mimetics. Oral bioavailability is approximately 60–70%, with absorption occurring in the upper GI tract. Food has a modest effect on Tmax (slightly delayed with food) but does not substantially reduce total bioavailability (AUC).
There is no subcutaneous or intramuscular formulation of MK-677 with human PK data. The compound exists exclusively as an oral agent. Its long half-life (~24 hours) further distinguishes it from all injectable GH secretagogues and is a direct consequence of its non-peptide molecular structure, which resists rapid enzymatic clearance.
MK-677 is not detected by standard WADA anti-doping panels or routine workplace/clinical urine drug screens, which are designed for opioids, cannabinoids, stimulants, benzodiazepines, and common PEDs. Unlike peptide GH secretagogues, MK-677 has no peptide backbone to detect via standard immunoassay or IRMS analysis.
Specialized detection would require HPLC-MS/MS methodology targeting MK-677 parent compound and/or metabolites. Based on the ~24-hour plasma half-life and typical urine concentration kinetics, the estimated urine detection window for such testing is approximately 24–72 hours after the last dose. Urine concentrations of parent drug and metabolites will decline in proportion to plasma clearance.
MK-677 (ibutamoren mesylate) is a synthetic spiropiperidine-derived non-peptide GHS-R1a agonist — a ghrelin receptor agonist engineered for oral bioavailability.[2] It mimics ghrelin's action at the growth hormone secretagogue receptor type 1a (GHS-R1a) on pituitary somatotrophs and in the hypothalamus, stimulating pulsatile GH release and downstream IGF-1 synthesis in the liver.
All endogenous and synthetic peptide GH secretagogues — ghrelin (28 amino acids), GHRP-2, GHRP-6, Ipamorelin, Hexarelin — are degraded by gastrointestinal proteases within minutes of oral ingestion, making subcutaneous injection the only viable delivery route. MK-677's non-peptide spiropiperidine structure has no amide bonds susceptible to protease cleavage, allowing it to survive GI transit and reach systemic circulation. This is not an incremental improvement — it represents a fundamentally different molecular approach to GHS-R1a agonism that Merck Research Laboratories spent years developing.
MK-677 stimulates GH secretion via both direct pituitary action and hypothalamic GHRH-potentiating effects. The GH release pattern differs from injectable GH secretagogues: rather than discrete high-amplitude GH pulses (as seen with GHRP-2 or Hexarelin), MK-677 produces a more sustained, lower-amplitude GH elevation that persists across the dosing interval due to its long half-life.[3] IGF-1 — which reflects cumulative hepatic GH receptor stimulation over time — rises gradually and reaches a new elevated plateau over 2–4 weeks of daily use. Nass et al. (2008) demonstrated significant increases in IGF-1 in elderly subjects after 6 months of daily 25mg MK-677, with effects on lean body mass and functional measures.[3]
MK-677 activates GHS-R1a receptors in the hypothalamus — the same receptors activated by ghrelin, the endogenous "hunger hormone." Hypothalamic GHS-R1a activation potently stimulates appetite via neuropeptide Y (NPY) and agouti-related protein (AgRP) signaling pathways. Appetite increase is a consistent and expected class effect of all ghrelin mimetics, including MK-677, and is dose-dependent. At 25mg/day, most users report a noticeable increase in hunger, particularly in the hours after dosing. This effect is pharmacologically separable from the GH-releasing effect — it is a direct receptor-level action, not secondary to GH or IGF-1.
Unlike GHRP-2 and Hexarelin, which cause significant cortisol elevation via ACTH stimulation, MK-677 at standard doses (10–25mg) does not produce clinically meaningful cortisol elevation in most subjects.[4] This is considered an advantage over cortisol-elevating GH secretagogues. However, MK-677 does have a known insulin-blunting effect: growth hormone itself opposes insulin signaling, and sustained GH/IGF-1 elevation can raise fasting glucose. At 25mg/day, fasting glucose increases of 3–10% have been observed in clinical trials. Individuals with pre-existing insulin resistance, impaired fasting glucose, or type 2 diabetes should exercise particular caution.
Known class effects and clinical observations from Phase 2/3 trials include: increased appetite (universal at therapeutic doses), water retention and mild edema (especially early in use), transient fasting glucose elevation (dose-dependent), fatigue and somnolence at higher doses, and morning numbness or paresthesias (carpal-tunnel-like syndrome from fluid retention) reported at 25mg/day.[3][4]
Sigalos and Pastuszak (2018) reviewed the safety profile of GH secretagogues and noted that MK-677 remains the most extensively clinically studied non-peptide GH secretagogue, with a moderately characterized safety profile in adults under 70, but significant caution warranted in the elderly and those with cardiometabolic risk.[5]
Model your plasma concentration, log doses, and track IGF-1 trends — all in one place. Free iOS app, no account required.
Download on App StoreMK-677 is commonly studied alongside other GH axis compounds. Compare pharmacokinetics and protocols:
Model plasma concentration over time, log oral doses, and track IGF-1 lab trends across your protocol. Free iOS app — no account required.
Download on App Store